Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Abbott Labs tops Q2 2018 profit estimates

Abbott Laboratories raised its 2018 full-year earnings forecast and reported a quarterly profit that beat analysts’ estimates, powered by higher sales across its businesses.

Read More »

Verily, ResMed Team Up On Sleep Apnea Joint Venture

Google’s Verily will team up with ResMed, a company that specializes in treating sleep disorders, to launch a joint business venture to address sleep apnea and other sleeping disorders.

Read More »

FDA Approves World’s First Long-Term Implantable Continuous Glucose Monitoring System

The U.S. FDA approved Senseonics Holdings’ Premarket Approval application to market the company’s Eversense Continuous Glucose Monitoring System to people with diabetes.

Read More »

DreaMed Receives FDA Approval for Diabetes Management Software

The U.S. FDA approved for marketing DreaMed Diabetes’ Advisor Pro software to help manage diabetes treatment.

Read More »

U.S. Food and Drug Administration Clears Wearable Device to Treat Opioid Addiction

DyAnsys Inc. announced that the U.S. Food and Drug Administration cleared the company’s auricular neurostimulation device, Drug Relief, to be used as an aid to reduce the symptoms of opioid withdrawal without narcotics.

Read More »

Five Prime Therapeutics Announces Collaboration with Roche to Develop Companion Diagnostics for Targeted Immuno-Oncology Investigational Drug Candidates

Five Prime Therapeutics announced a collaboration with Roche to develop immunohistochemistry companion diagnostic assays for use with the clinical-stage biotechnology company’s first-in-class investigational drug candidates: the anti-FGFR2b antibody bemarituzumab (also known as FPA144) and the a B7-H4 antibody FPA150.

Read More »

GSK Submits Regulatory Application in Japan for Once-Daily Single Inhaler Triple Therapy FF/UMEC/VI for Patients with COPD

GlaxoSmithKline plc and Innoviva Inc. announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and Welfare for once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI 100/62.5/25 mcg) under the proposed brand name of Trelegy Ellipta for the treatment of adults with chronic obstructive pulmonary disease. This is the first regulatory filing to be made in Japan for a triple COPD therapy in a single inhaler.

Read More »

Foundation Medicine Establishes Immuno-Oncology Companion Diagnostics Collaboration with Merck

Foundation Medicine Inc. announced a collaboration with Merck & Co. to develop companion diagnostic tests for use with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy and the first approved immunotherapy for microsatellite instability high or mismatch repair deficient solid tumors.

Read More »

Newest Generation Of Leading Heart Stent Approved In U.S. For People With Coronary Artery Disease

Abbott received approval from the U.S. Food and Drug Administration for XIENCE Sierra, the newest generation of the gold-standard XIENCE everolimus-eluting coronary stent system.

Read More »

FDA says Mylan’s EpiPen is in shortage

U.S. regulators said Mylan NV’s EpiPen products are in shortage, due to manufacturing delays that are creating intermittent supply constraints of the emergency allergy treatment.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

December 2018 Focus: Healthcare Agency Roundtable, Mobile Marketing, and more!

Subscribe

Ad Right Bottom